Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Has Average Price Target of $21.85 According to Brokerages

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have received an average recommendation of “Hold” from the thirteen ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $21.85.

Several equities research analysts recently commented on the stock. Chardan Capital lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a research note on Tuesday, August 18th. HC Wainwright restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, October 20th. JPMorgan Chase & Co. lowered Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, October 20th. Jefferies Financial Group cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research note on Monday, October 19th. Finally, Weiss Ratings cut Eyepoint Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday.

View Our Latest Stock Report on EYPT

Eyepoint Pharmaceuticals Stock Down 3.8%

NASDAQ:EYPT opened at $0.30 on Wednesday. The firm’s fifty day simple moving average is $2.16 and its 200 day simple moving average is $10.10. The stock has a market cap of $25.51 million, a P/E ratio of -0.07 and a beta of 1.84. Eyepoint Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.14). Eyepoint Pharmaceuticals had a negative return on equity of 168.83% and a negative net margin of 13,281.23%. The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.23 million. On average, analysts expect that Eyepoint Pharmaceuticals will post -3.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several large investors have recently modified their holdings of the stock. KBC Group NV bought a new position in Eyepoint Pharmaceuticals in the 1st quarter worth about $29,000. Integrated Wealth Concepts LLC purchased a new stake in Eyepoint Pharmaceuticals during the 2nd quarter valued at about $72,000. Cyndeo Wealth Partners LLC increased its stake in Eyepoint Pharmaceuticals by 46.8% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock valued at $116,000 after purchasing an additional 11,329 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Eyepoint Pharmaceuticals during the 2nd quarter valued at about $161,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter valued at about $390,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

(Get Free Report)

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.

Recommended Stories

Analyst Recommendations for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.